Skip to main content

Genomic Solutions Licenses Low-Density Microarray Technology from Affymetrix

NEW YORK, Jan 4 – Affymetrix has granted Genomic Solutions a non-exclusive license to commercialize low and medium density microarrays, the companies announced Thursday.

Under the agreement, Genomic Solutions will provide Affymetrix with fees and royalty payments on arrays it sells. Genomic Solutions plans to build upon its line of GeneMap microarrays to include human, mouse and rat array sets as well as arrays specific to diseases and biochemical pathways, a company statement said. Currently, Genomic Solutions only offers a cancer-based microarray.

" Genomic Solutions is pleased to be able to provide this license to our GeneMap array product customers,"  Shannon Richey, vice president of the genomic business unit at Genomic Solutions, said in a statement. " With this license agreement, Genomic Solutions is now well-positioned to provide a broader offering of cDNA and oligonucleotide arrays to the marketplace.

Over 25 companies have licensed array technology from Affymetrix, which holds a sizeable portion of the intellectual property in the field.   

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.